The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Insights and Analysis
AHA Senior Vice President and Chief Medical Officer Jay Bhatt, D.O., and Shantanu Agrawal, M.D., president and CEO of the National Quality Forum, highlight a…
Insights and Analysis
One great way to improve capacity and prepare for the future workforce needs—as well as respond to consumers’ desires—is to fully embrace telehealth.
Chairperson's File
More than three-quarters of U.S.
Headline
The Centers for Medicare & Medicaid Services Friday finalized changes to the Medicare Advantage and prescription drug programs for contract year 2020.
Headline
The AHA today shared with House and Senate members of the Congressional Telehealth Caucus recommendations for improving and expanding access to telehealth. 
Headline
The AHA and the National Quality Forum today released a guide to help hospitals and health systems working to deliver innovative, high-quality telebehavioral…